| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/14787210.5.4.613 |
| P698 | PubMed publication ID | 17678425 |
| P2093 | author name string | Stefan Weiss | |
| Inga Zerr | |||
| Chantal Zuber | |||
| Daphne Nikles | |||
| Karen Vana | |||
| Heike Ludewigs | |||
| P2860 | cites work | Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. | Q48263573 |
| Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice | Q48289964 | ||
| Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt-Jakob disease | Q48499196 | ||
| Intracerebroventricular delivery of dominant negative prion protein in a mouse model of iatrogenic Creutzfeldt-Jakob disease after dura graft transplantation | Q48506670 | ||
| Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD. | Q48525187 | ||
| Effectiveness of anthracycline against experimental prion disease in Syrian hamsters | Q48706421 | ||
| Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies | Q48800686 | ||
| MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement | Q48852997 | ||
| Jakob-Creutzfeldt disease: treatment by amantadine | Q49386394 | ||
| A trans-dominant negative 37kDa/67kDa laminin receptor mutant impairs PrP(Sc) propagation in scrapie-infected neuronal cells. | Q51809715 | ||
| Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. | Q51816912 | ||
| A novel generation of heparan sulfate mimetics for the treatment of prion diseases. | Q51834544 | ||
| Neurocognitive differential diagnosis of dementing diseases: Alzheimer's Dementia, Vascular Dementia, Frontotemporal Dementia, and Major Depressive Disorder. | Q51979111 | ||
| Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice. | Q54037114 | ||
| Porphyrin and phthalocyanine antiscrapie compounds. | Q54061556 | ||
| Potent inhibition of scrapie-associated PrP accumulation by congo red | Q54131452 | ||
| Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. | Q54197273 | ||
| Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. | Q54528615 | ||
| Failure of interferon to modify Creutzfeldt-Jakob disease | Q55260779 | ||
| Cationic Lipopolyamines Induce Degradation of PrPSc in Scrapie-Infected Mouse Neuroblastoma Cells | Q57375636 | ||
| Monoclonal antibodies inhibit prion replication and delay the development of prion disease | Q59053964 | ||
| Branched polyamines cure prion-infected neuroblastoma cells | Q24529092 | ||
| Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease | Q24550300 | ||
| Elimination of prions by branched polyamines and implications for therapeutics | Q24646752 | ||
| Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice | Q24673105 | ||
| Formation of native prions from minimal components in vitro | Q24676353 | ||
| Akinetic mutism as a classification criterion for the diagnosis of Creutzfeldt-Jakob disease | Q24680088 | ||
| Evaluation of quinacrine treatment for prion diseases | Q24682427 | ||
| NMR structure of the mouse prion protein domain PrP(121-231) | Q27733163 | ||
| Mice devoid of PrP are resistant to scrapie | Q28249108 | ||
| Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor | Q28363055 | ||
| Production of cattle lacking prion protein. | Q30492928 | ||
| Tetracyclines affect prion infectivity | Q30531528 | ||
| How to improve the clinical diagnosis of Creutzfeldt-Jakob disease | Q30584961 | ||
| Clinical diagnosis and differential diagnosis of CJD and vCJD. With special emphasis on laboratory tests | Q30698122 | ||
| Novel single chain antibodies to the prion protein identified by phage display | Q30826530 | ||
| Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease. | Q30983435 | ||
| Clinical course in young patients with sporadic Creutzfeldt-Jakob disease | Q30995751 | ||
| Anti-amyloidogenic activity of tetracyclines: studies in vitro. | Q31861027 | ||
| Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication | Q33225026 | ||
| Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. | Q33248701 | ||
| Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies | Q33843281 | ||
| Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody | Q33930771 | ||
| Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease | Q33933969 | ||
| Dominant-negative inhibition of prion replication in transgenic mice | Q34191612 | ||
| A prion protein epitope selective for the pathologically misfolded conformation | Q34201802 | ||
| Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. | Q34273746 | ||
| A porphyrin increases survival time of mice after intracerebral prion infection | Q34352240 | ||
| A new variant of Creutzfeldt-Jakob disease in the UK. | Q34374893 | ||
| Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects | Q34380330 | ||
| Mucosal vaccination delays or prevents prion infection via an oral route. | Q34416637 | ||
| Suppression of prion protein in livestock by RNA interference. | Q34506076 | ||
| Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides | Q34509751 | ||
| Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. | Q34509758 | ||
| Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease | Q34511219 | ||
| Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis | Q34521384 | ||
| CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. | Q34559367 | ||
| Infectious prions in the saliva and blood of deer with chronic wasting disease | Q34571835 | ||
| Bovine prion is endocytosed by human enterocytes via the 37 kDa/67 kDa laminin receptor. | Q35085199 | ||
| MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie | Q35121108 | ||
| Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease | Q35462665 | ||
| The neuropsychology of variant CJD: a comparative study with inherited and sporadic forms of prion disease. | Q35486440 | ||
| Early cognitive decline in Creutzfeldt-Jakob disease associated with human growth hormone treatment. | Q35560261 | ||
| Prion protein-specific antibodies for therapeutic intervention of transmissible spongiform encephalopathies | Q36407253 | ||
| Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines | Q36518232 | ||
| A systematic review of prion therapeutics in experimental models | Q36525632 | ||
| Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation | Q36581272 | ||
| Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc | Q36672125 | ||
| Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy | Q36676179 | ||
| Therapeutic approaches targeting the prion receptor LRP/LR. | Q36820454 | ||
| Creutzfeldt-Jakob disease treated with amantidine: A report of two cases | Q37093073 | ||
| Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. | Q37569845 | ||
| Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models | Q37730189 | ||
| DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation | Q38295713 | ||
| Prion-protein-specific aptamer reduces PrPSc formation | Q38363420 | ||
| DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge | Q38761934 | ||
| Short report: Creutzfeldt-Jakob disease treated with amantadine | Q39227068 | ||
| The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein | Q39644598 | ||
| Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations. | Q39692874 | ||
| Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation. | Q39719132 | ||
| Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases | Q40166050 | ||
| Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells. | Q40168614 | ||
| The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes | Q40245615 | ||
| Amyloid deposits and amyloidosis: the beta-fibrilloses (second of two parts). | Q40283366 | ||
| Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. | Q40477337 | ||
| Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. | Q40483672 | ||
| Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation | Q40504536 | ||
| The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. | Q40537139 | ||
| PrPSc binding antibodies are potent inhibitors of prion replication in cell lines. | Q40558013 | ||
| Knock-down of the 37-kDa/67-kDa laminin receptor in mouse brain by transgenic expression of specific antisense LRP RNA. | Q40569086 | ||
| Specific inhibition of pathological prion protein accumulation by small interfering RNAs | Q40646170 | ||
| Inhibition of scrapie-associated PrP accumulation. Probing the role of glycosaminoglycans in amyloidogenesis | Q40654314 | ||
| The 37 kDa/67 kDa laminin receptor is required for PrP(Sc) propagation in scrapie-infected neuronal cells | Q40666067 | ||
| Filipin prevents pathological prion protein accumulation by reducing endocytosis and inducing cellular PrP release | Q40734071 | ||
| The anti-prion activity of Congo red. Putative mechanism | Q41062006 | ||
| The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells | Q41077192 | ||
| Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP. | Q41904973 | ||
| Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate | Q42765732 | ||
| Prion (PrPSc)-specific epitope defined by a monoclonal antibody | Q42816365 | ||
| Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada | Q43218822 | ||
| Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein | Q43522858 | ||
| Effects of the polyene antibiotic derivative MS-8209 on the astrocyte lysosomal system of scrapie-infected hamsters | Q44023828 | ||
| Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease | Q44383471 | ||
| Amphotericin B binds to amyloid fibrils and delays their formation: a therapeutic mechanism? | Q44446729 | ||
| Prophylactic and therapeutic effects of phthalocyanine tetrasulfonate in scrapie-infected mice | Q44559545 | ||
| Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study | Q44790692 | ||
| Differential diagnosis of 201 possible Creutzfeldt-Jakob disease patients | Q44795783 | ||
| Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease | Q45239690 | ||
| Antibodies inhibit prion propagation and clear cell cultures of prion infectivity | Q46161882 | ||
| Polymerization of murine recombinant prion protein in nucleic acid solution | Q46243624 | ||
| Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. | Q46501596 | ||
| Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type | Q46750178 | ||
| KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity | Q46804222 | ||
| Results of quinacrine administration to patients with Creutzfeldt-Jakob disease | Q48087933 | ||
| Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease | Q48126727 | ||
| RNA molecules stimulate prion protein conversion | Q48170423 | ||
| Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance | Q48181910 | ||
| P433 | issue | 4 | |
| P921 | main subject | prion protein family | Q24724413 |
| P304 | page(s) | 613-630 | |
| P577 | publication date | 2007-08-01 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Therapeutic approaches for prion disorders | |
| P478 | volume | 5 |
| Q36503630 | A Fluorescent Oligothiophene-Bis-Triazine ligand interacts with PrP fibrils and detects SDS-resistant oligomers in human prion diseases. |
| Q37080701 | Anti-LRP/LR antibody W3 hampers peripheral PrPSc propagation in scrapie infected mice |
| Q37514313 | Antibody-based immunotherapeutic attempts in experimental animal models of prion diseases |
| Q37585423 | Complex polyamines: unique prion disaggregating compounds. |
| Q37627076 | De novo mammalian prion synthesis |
| Q42769170 | Detection of four novel polymorphisms in PrP gene of Pakistani sheep (Damani and Hashtnagri) and goats (Kamori and Local Hairy) breeds |
| Q48832453 | Development of antibody fragments for immunotherapy of prion diseases |
| Q46041493 | Dual modulation of ERK1/2 and p38 MAP kinase activities induced by minocycline reverses the neurotoxic effects of the prion protein fragment 90-231. |
| Q31023317 | From high-throughput cell culture screening to mouse model: identification of new inhibitor classes against prion disease |
| Q33408553 | Inoculation of scrapie with the self-assembling RADA-peptide disrupts prion accumulation and extends hamster survival |
| Q33730451 | Multiple functions of the 37/67-kd laminin receptor make it a suitable target for novel cancer gene therapy |
| Q38234645 | Multitarget ligands and theranostics: sharpening the medicinal chemistry sword against prion diseases. |
| Q33560047 | New engineered antibodies against prions |
| Q39455005 | Oligomeric-induced activity by thienyl pyrimidine compounds traps prion infectivity |
| Q37812614 | Patented biological approaches for the therapeutic modulation of the 37 kDa/67 kDa laminin receptor |
| Q43003329 | Polymorphisms of the prion protein gene (PRNP) in a Serbian population. |
| Q48290634 | Recombinant single-chain antibody with the Trojan peptide penetratin positioned in the linker region enables cargo transfer across the blood-brain barrier |
| Q38139218 | Single-chain fragment variable passive immunotherapies for neurodegenerative diseases |
| Q33809258 | Specific binding of the pathogenic prion isoform: development and characterization of a humanized single-chain variable antibody fragment |
| Q39856446 | The 37/67 kDa laminin receptor (LR) inhibitor, NSC47924, affects 37/67 kDa LR cell surface localization and interaction with the cellular prion protein. |
| Q39990152 | siRNA-mediated silencing of the 37/67-kDa high affinity laminin receptor in Hep3B cells induces apoptosis. |
Search more.